The first known coronavirus disease 2019 (COVID‐19) related hospitalization in New York City was reported at Columbia University Irving Medical Center/NewYork‐Presbyterian Hospital. Since then, the rapid increase in the number of patients with COVID‐19 associated with acute respiratory distress syndrome (ARDS)[^1^](#jgs16507-bib-0001){ref-type="ref"} and high rates of mortality[2](#jgs16507-bib-0002){ref-type="ref"}, [3](#jgs16507-bib-0003){ref-type="ref"} has highlighted the critical need for high‐quality end‐of‐life care. On March 31, 2020, an eight‐bed Palliative Care Unit (PCU) was established at our institution for patients with COVID‐19 whose surrogates opted to not initiate or continue life‐sustaining therapies. To our knowledge, this is the first report describing COVID‐19 patients receiving comfort‐directed care.

This case series aims to describe the characteristics and palliative care needs in patients admitted to the PCU at Columbia University Irving Medical Center/NewYork‐Presbyterian Hospital to inform other clinicians caring for this population at the end of life.

METHODS {#jgs16507-sec-0002}
=======

Deceased patients with confirmed severe acute respiratory syndrome coronavirus 2 infection by polymerase chain reaction testing of a nasopharyngeal sample, admitted to the PCU at Columbia University Irving Medical Center/NewYork‐Presbyterian Hospital between March 31, 2020, and April 10, 2020, were included.

Before data collection, a waiver was obtained from the Columbia University institutional review board. Deidentified patient data were collected from the electronic medical record Epic Hyperspace and analyzed using Microsoft Excel. Laboratory testing was reviewed at PCU admission. Patient outcome data were evaluated at time of death. Due to the descriptive nature of this case series, no analysis for statistical significance was performed.

RESULTS {#jgs16507-sec-0003}
=======

A total of 30 patients were included in this case series (mean age = 84.5 years; 53% male) (Table [1](#jgs16507-tbl-0001){ref-type="table"}). Most patients were of Hispanic origin (20 \[66.7%\]), followed by white (4 \[13.3%\]). All 30 patients had comorbidities before hospital admission, with 70% of patients having more than one comorbidity. Twenty‐four patients (80%) had metabolic abnormalities, with hypernatremia observed in 17 patients (57%). Before PCU admission, all 30 patients developed ARDS, with 29 (97%) requiring supplemental oxygen.

###### 

Baseline Characteristics of 30 Patients With COVID‐19 at Presentation to the PCU

  Baseline Characteristics                                                       No. (%) of Patients[^a^](#jgs16507-note-0002){ref-type="fn"}
  ------------------------------------------------------------------------------ --------------------------------------------------------------
  Demographics                                                                   
  Age, mean (range), y                                                           84.5 (71‐97)
  Sex                                                                            
  Male                                                                           14 (46.7)
  Female                                                                         16 (53.3)
  Ethnicity/race                                                                 
  Hispanic, Latino, or Spanish origin                                            20 (66.7)
  White                                                                          4 (13.3)
  Black or African American                                                      2 (6.7)
  Declined to answer                                                             2 (6.7)
  Preadmission comorbidities                                                     
  Dementia                                                                       14 (46.7)
  Asthma                                                                         2 (6.7)
  Coronary artery disease                                                        8 (26.7)
  Hypertension                                                                   24 (80.0)
  Chronic obstructive pulmonary disease                                          5 (16.7)
  Congestive heart failure                                                       4 (13.3)
  Diabetes                                                                       15 (50.0)
  Cancer                                                                         7 (23.3)
  Prostate                                                                       4 (13.3)
  Breast                                                                         1 (3.3)
  Bladder                                                                        1 (3.3)
  Lung/breast/ovarian                                                            1 (3.3)
  Obstructive sleep apnea                                                        0 (0.0)
  Chronic kidney disease                                                         12 (40.0)
  End‐stage kidney disease                                                       1 (3.3)
  History of solid organ transplant                                              0 (0.0)
  Immunosuppression[^b^](#jgs16507-note-0003){ref-type="fn"}                     2 (6.7)
  Cirrhosis                                                                      0 (0.0)
  Total with \>1 comorbidity                                                     21 (70.0)
  Admission symptoms                                                             
  Cough                                                                          17 (56.7)
  Shortness of breath                                                            24 (80.0)
  Fever[^c^](#jgs16507-note-0004){ref-type="fn"}                                 15 (50.0)
  Admission laboratory measures                                                  
  Hypernatremia                                                                  17 (56.7)
  Other metabolic abnormalities                                                  21 (70.0)
  Bacterial coinfection[^d^](#jgs16507-note-0005){ref-type="fn"}                 5 (16.7)
  COVID‐19 manifestation before PCU admission                                    
  Cardiomyopathy                                                                 1 (3.3)
  Acute kidney injury                                                            8 (26.7)
  Acute respiratory distress syndrome[^e^](#jgs16507-note-0006){ref-type="fn"}   30 (100.0)
  Use of nasal cannula                                                           19 (63.3)
  Use of nonrebreather                                                           29 (96.7)
  Use of high‐flow oxygen therapy \>15 L/min                                     0 (0.0)
  Use of noninvasive positive pressure ventilation                               0 (0.0)
  Received mechanical ventilation[^f^](#jgs16507-note-0007){ref-type="fn"}       0 (0.0)
  Use of antibiotics                                                             18 (60.0)
  Use of vasopressors                                                            3 (10.0)

Abbreviations: COVID‐19, coronavirus disease 2019; PCU, Palliative Care Unit.

Unless otherwise indicated.

Defined as outpatient prescription of greater than 10 mg/d of prednisone or an equivalent, use of chemotherapy, or use of nonsteroidal immunosuppressive agents for solid organ transplant or for an autoimmune disease.

Defined as a temperature of greater than 100°F.

Two patients had positive blood cultures and three patients had positive urine cultures.

Definition and severity according to the Berlin Criteria.

Patients on mechanical ventilation who were palliatively extubated were not transferred to the PCU, and therefore, not included in this study.

On admission to the PCU, the most common symptom observed was dyspnea (30 \[100%\]), followed by delirium (22 \[73%\]), pain (10 \[33%\]), and anxiety (10 \[33%\]) (Table [2](#jgs16507-tbl-0002){ref-type="table"}). Intravenous morphine (23 \[77%\]) and hydromorphone (11 \[37%\]) were the most commonly used medications. A total of 62 visits and calls were made by chaplains and social workers to provide spiritual and psychosocial support (eg, offering end‐of‐life prayers to patients and assisting family members with funeral planning).

###### 

End‐of‐Life Care Needs and Time Course

  Variable                                                     No. (%) of Patients[^a^](#jgs16507-note-0009){ref-type="fn"}
  ------------------------------------------------------------ --------------------------------------------------------------
  Symptoms observed                                            
  Dyspnea                                                      30 (100.0)
  Delirium                                                     22 (73.3)
  Pain                                                         10 (33.3)
  Anxiety                                                      10 (33.3)
  Nausea/vomiting                                              4 (13.3)
  Myoclonus                                                    4 (13.3)
  Medications used                                             
  Morphine                                                     23 (76.7)
  Hydromorphone                                                11 (36.7)
  Haloperidol                                                  11 (36.7)
  Lorazepam                                                    21 (70.0)
  Morphine IV equivalent infusion rate, median (range), mg/h   2 (1‐6)
  Morphine IV equivalent bolus, median (range), mg             3.3 (1.3‐10)
  Support provided                                             
  From social worker                                           24 (80.0)
  Total No. of calls/visits made                               51
  From chaplaincy                                              11 (36.7)
  No. of calls/visits made                                     11
  From family/friends visiting                                 5 (16.7)
  End‐of‐life decision making and time to death                
  ED to DNR/DNI order, mean (range), h                         20.0 (0‐163)
  DNR/DNI to death, mean (range), h                            100.5 (21‐219)
  PCU admission to death, mean (range), h                      34.6 (3‐104)

Abbreviations: DNI, do not intubate; DNR, do not resuscitate; ED, emergency department; IV, intravenous; PCU, Palliative Care Unit.

Unless otherwise indicated.

The average length of stay in the PCU was 34.6 hours or 1.4 days.

DISCUSSION {#jgs16507-sec-0004}
==========

We report the characteristics and palliative care needs of patients with severe COVID‐19 infection who have forgone life‐sustaining treatments and received comfort‐directed care.

Consistent with other studies,[4](#jgs16507-bib-0004){ref-type="ref"}, [5](#jgs16507-bib-0005){ref-type="ref"} we observed an older age group with high rates of comorbidities. Given the high proportion of patients with metabolic abnormalities on hospital admission, further study is needed to explore the potential association between severity of metabolic disarray and its impact on patient outcomes.

Dyspnea and delirium were the most commonly observed symptoms in dying patients with COVID‐19. Relatively low doses of morphine, hydromorphone, and lorazepam were needed for symptom control. The present study also highlights the crucial role of social workers and chaplains in providing psychosocial and spiritual support to patients and families, especially given the limited degree of contact most family members had with their loved one.

The limitations of this study include the small sample size from one hospital center, ethnic and racial makeup of the population given the location in New York City, as well as possible selection bias by admitting moribund patients who are more imminently dying due to limited bed availability in the PCU. Nonetheless, this study can be instructive to other institutions to understand and prepare for the palliative care needs in patients dying from COVID‐19.
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